Indocyanine Green Versus Blue Dye for Detection of Sentinel Lymph Node In Endometrial Cancer

Sponsor
Centre hospitalier de l'Université de Montréal (CHUM) (Other)
Overall Status
Completed
CT.gov ID
NCT02564276
Collaborator
(none)
132
1
2
17
7.8

Study Details

Study Description

Brief Summary

To determine the difference in the proportion of hemipelves with successful detection of Sentinel Lymph Node according to the dye used (indocyanine green with near-infrared imaging vs blue dye) in women with endometrial cancer.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Sentinel lymph node biopsy
Phase 3

Detailed Description

In the past few years, Sentinel Lymph Node (SLN) procedure has emerged as an interesting solution to the debate on lymphadenectomy in endometrial cancer. Using blue-dye is inexpensive but results in an unsatisfactory detection rate of SLN. IndoCyanine Green (ICG) with near-infrared imaging is a novel technology for SLN mapping and initial reports on the use of ICG have shown high detection rate. In the present study, we aim to determine precisely the increase in detection rate of SLN associated with the use of ICG instead of blue dye. This randomized controlled trial will include patients with preoperative stage I endometrial carcinoma. All included women will undergo SLN mapping with blue dye in one hemipelvis and ICG in the other hemipelvis. Randomization will concern the side of the hemipelvis in which blue dye vs ICG mapping is used, so that the patient's contralateral hemipelvis will serve as a control to her ipsilateral hemipelvis. The primary endpoint is the difference in the proportion of hemipelves with successful detection of SLN according to the dye used. The unique precise information gained from the present study will contribute to determine whether the benefit of the use of ICG over blue dye is sufficient to justify the expense of its use.

Study Design

Study Type:
Interventional
Actual Enrollment :
132 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Diagnostic
Official Title:
Indocyanine Green Versus Blue Dye for Detection of Sentinel Lymph Node In Endometrial Cancer
Study Start Date :
Feb 1, 2016
Actual Primary Completion Date :
Apr 1, 2017
Actual Study Completion Date :
Jul 1, 2017

Arms and Interventions

Arm Intervention/Treatment
Experimental: Indocyanine Green on the right side

Indocyanine Green will be injected on the right side of the cervix and Methylene blue on the left side of the cervix.

Procedure: Sentinel lymph node biopsy

Experimental: Methylene Blue on the right side

Methylene blue will be injected on the right side of the cervix and Indocyanine Green on the left side of the cervix.

Procedure: Sentinel lymph node biopsy

Outcome Measures

Primary Outcome Measures

  1. the difference in the proportion of hemipelves with successful detection of SLN according to the dye used [at time of surgery]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • all patients with endometrial carcinoma proven by endometrial biopsy or curettage AND

  • preoperative FIGO (International Federation of Gynecology and Obstetrics) stage I AND

  • intended for staging via laparoscopic or robotic surgery AND

  • Patients must be older than 18 year-old, able to read French or English.

Exclusion Criteria:
  • preoperative FIGO stages II to IV

  • previous pelvic or paraaortic lymphadenectomy or radiotherapy

  • surgery that could change the uterine lymphatic drainage (myomectomy)

  • iodine allergy

  • pregnancy.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Centre Hospitalier Universitaire Montréal Hôpital Saint Luc Montréal Quebec Canada

Sponsors and Collaborators

  • Centre hospitalier de l'Université de Montréal (CHUM)

Investigators

  • Principal Investigator: Béatrice Cormier, MD, Centre hospitalier de l'Université de Montréal (CHUM)

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Centre hospitalier de l'Université de Montréal (CHUM)
ClinicalTrials.gov Identifier:
NCT02564276
Other Study ID Numbers:
  • CE 15.114
First Posted:
Sep 30, 2015
Last Update Posted:
Jan 25, 2018
Last Verified:
Jun 1, 2016
Keywords provided by Centre hospitalier de l'Université de Montréal (CHUM)
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 25, 2018